📊 CC Key Takeaways
Investment Thesis
Chemours is facing severe operational distress with negative operating and net income despite stable revenue, indicating fundamental business deterioration. The company's extremely high leverage (16.4x debt-to-equity) combined with negative interest coverage and minimal profitability creates significant financial risk and sustainability concerns. Even positive free cash flow of $51M is insufficient to service $4.1B in long-term debt or address the underlying operational profitability crisis.
CC Strengths
- Positive operating cash flow of $264M provides near-term liquidity despite net losses
- Current ratio of 1.78x indicates adequate short-term liquidity to meet obligations
- Free cash flow of $51M demonstrates some cash generation capacity from operations
CC Risks
- Severe negative profitability with -6.6% net margin and -$386M net income indicates structural operational failure
- Extreme leverage at 16.4x debt-to-equity with $4.1B long-term debt against only $250M equity creates default risk
- Negative interest coverage of -1.0x means operating income cannot cover debt service, threatening financial stability
- Negative ROE of -154.4% and ROA of -5.2% show value destruction for shareholders and asset base
- Operating margin of -4.8% indicates core business is unprofitable before financing costs
Key Metrics to Watch
- Path to operating profitability and positive operating margins
- Debt reduction progress and debt-to-equity ratio improvement
- Interest coverage ratio trajectory and debt service sustainability
- Net income recovery and return to profitability
- Free cash flow sustainability and cash burn rate
CC Financial Metrics
💡 AI Analyst Insight
The relatively thin 0.9% FCF margin may limit capital allocation flexibility.
CC Profitability Ratios
CC vs Default Sector
How Chemours Co compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CC Balance Sheet & Liquidity
CC 5-Year Financial Trend
5-Year Trend Summary: Chemours Co's revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $-1.70 indicates the company is currently unprofitable.
CC Growth Metrics (YoY)
CC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.5B | -$32.0M | $-0.22 |
| Q2 2025 | $1.6B | $60.0M | $0.39 |
| Q1 2025 | $1.4B | -$4.0M | $-0.03 |
| Q3 2024 | $1.5B | $12.0M | $0.08 |
| Q2 2024 | $1.5B | $70.0M | $0.46 |
| Q1 2024 | $1.4B | $52.0M | $0.34 |
| Q3 2023 | $1.5B | $20.0M | $0.13 |
| Q2 2023 | $1.6B | $201.0M | $1.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CC Capital Allocation
CC SEC Filings
Access official SEC EDGAR filings for Chemours Co (CIK: 0001627223)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CC
What is the AI rating for CC?
Chemours Co (CC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CC's key strengths?
Positive operating cash flow of $264M provides near-term liquidity despite net losses. Current ratio of 1.78x indicates adequate short-term liquidity to meet obligations.
What are the risks of investing in CC?
Severe negative profitability with -6.6% net margin and -$386M net income indicates structural operational failure. Extreme leverage at 16.4x debt-to-equity with $4.1B long-term debt against only $250M equity creates default risk.
What is CC's revenue and growth?
Chemours Co reported revenue of $5.8B.
Does CC pay dividends?
Chemours Co pays dividends, with $78.0M distributed to shareholders in the trailing twelve months.
Where can I find CC SEC filings?
Official SEC filings for Chemours Co (CIK: 0001627223) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CC's EPS?
Chemours Co has a diluted EPS of $-2.57.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.